B6.FVB-Tg(S100A8-BCL2)1Lgs/Orl

Status	Available to order
EMMA ID	EM:14664
International strain name	B6.FVB-Tg(S100A8-BCL2)1Lgs/Orl
Alternative name	FVB/NMRP8hBCL-2 B6
Strain type	Transgenic Strains
Allele/Transgene symbol	Tg(S100A8-BCL2)1Lgs
Gene/Transgene symbol	Tg(S100A8-BCL2)1Lgs

Information from provider

Provider	Irv Weissman
Provider affiliation	Ludwig Centre for Cancer Stem Cell Research and Medicine, Stanford University School of Medicine
Genetic information	Human BCL-2 driven by the myeloid MRP8 promoter
Phenotypic information	Homozygous: Not bred to homozygosity and maintained as hemizygous Heterozygous: Increased bone marrow blast cells
Breeding history	Initial strain EM:12211 on FVB/N background was backcrossed 8 times on C57BL/6
References	Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice.;Lagasse E, Weissman I L, ;1997;Cell;89;1021-31; 9215625 Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia.;Traver D, Akashi K, Weissman I L, Lagasse E, ;1998;Immunity;9;47-57; 9697835 BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia.;Kogan S C, Brown D E, Shultz D B, Truong B T, Lallemand-Breitenbach V, Guillemin M C, Lagasse E, Weissman I L, Bishop J M, ;2001;The Journal of experimental medicine;193;531-43; 11181704 Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias.;Jaiswal Siddhartha, Traver David, Miyamoto Toshihiro, Akashi Koichi, Lagasse Eric, Weissman Irving L, ;2003;Proceedings of the National Academy of Sciences of the United States of America;100;10002-7; 12890867 Over-expression of Bcl-2 provides protection in septic mice by a trans effect.;Iwata Akiko, Stevenson Vicki Morgan, Minard Annie, Tasch Michael, Tupper Joan, Lagasse Eric, Weissman Irving, Harlan John M, Winn Robert K, ;2003;Journal of immunology (Baltimore, Md. : 1950);171;3136-41; 12960340 BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.;Omidvar Nader, Kogan Scott, Beurlet Stephanie, le Pogam Carole, Janin Anne, West Robert, Noguera Maria-Elena, Reboul Murielle, Soulie Annie, Leboeuf Christophe, Setterblad Niclas, Felsher Dean, Lagasse Eric, Mohamedali Azim, Thomas N Shaun B, Fenaux Pierre, Fontenay Michaela, Pla Marika, Mufti Ghulam J, Weissman Irving, Chomienne Christine, Padua Rose Ann, ;2007;Cancer research;67;11657-67; 18089795
Homozygous fertile	not known
Homozygous viable	not known
Homozygous matings required	no
Immunocompromised	no

Information from EMMA

Archiving centre	Institut de Transgenose, INTRAGENE, Orléans, France
Animals used for archiving	heterozygous C57BL/6J

Literature references

Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice.;Lagasse E, Weissman I L, ;1997;Cell;89;1021-31; 9215625
Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia.;Traver D, Akashi K, Weissman I L, Lagasse E, ;1998;Immunity;9;47-57; 9697835
BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia.;Kogan S C, Brown D E, Shultz D B, Truong B T, Lallemand-Breitenbach V, Guillemin M C, Lagasse E, Weissman I L, Bishop J M, ;2001;The Journal of experimental medicine;193;531-43; 11181704
Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias.;Jaiswal Siddhartha, Traver David, Miyamoto Toshihiro, Akashi Koichi, Lagasse Eric, Weissman Irving L, ;2003;Proceedings of the National Academy of Sciences of the United States of America;100;10002-7; 12890867
Over-expression of Bcl-2 provides protection in septic mice by a trans effect.;Iwata Akiko, Stevenson Vicki Morgan, Minard Annie, Tasch Michael, Tupper Joan, Lagasse Eric, Weissman Irving, Harlan John M, Winn Robert K, ;2003;Journal of immunology (Baltimore, Md. : 1950);171;3136-41; 12960340
BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.;Omidvar Nader, Kogan Scott, Beurlet Stephanie, le Pogam Carole, Janin Anne, West Robert, Noguera Maria-Elena, Reboul Murielle, Soulie Annie, Leboeuf Christophe, Setterblad Niclas, Felsher Dean, Lagasse Eric, Mohamedali Azim, Thomas N Shaun B, Fenaux Pierre, Fontenay Michaela, Pla Marika, Mufti Ghulam J, Weissman Irving, Chomienne Christine, Padua Rose Ann, ;2007;Cancer research;67;11657-67; 18089795

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740^*
Rederivation of mice from frozen stock, delivery time available upon request . €3880^*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

^* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.